NCT04492878View on ClinicalTrials.gov

Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

January 18, 2021

Study Completion Date

January 18, 2021

Conditions
Dry EyeDry Eye SyndromesSevere Keratitis
Interventions
DRUG

IKERVIS®1mg/mL

One drop of study medication once daily in each eye at bedtime during 90 days.

Trial Locations (1)

47011

Institute of Applied Ophthalmobiology (IOBA), Valladolid

All Listed Sponsors
collaborator

Santen Oy

INDUSTRY

lead

Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

OTHER

NCT04492878 - Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment | Biotech Hunter | Biotech Hunter